According to this recent study, community pharmacies and pharmacists have the potential to be change agents in skin cancer prevention by providing education on sun protection or detection and by promoting sun-safety behaviors.
According to the PIVOT IO 001 study, Bempegaldesleukin (BEMPEG) plus nivolumab (NIVO) combination therapy provided no additional clinical benefit compared with NIVO monotherapy in patients with previously untreated unresectable or metastatic melanoma. A higher incidence of treatment-related adverse events with a lack of added efficacy was noted with BEMPEG plus NIVO versus NIVO alone.
According to this recent study, better patient education regarding the reduction of skin cancers with oral nicotinamide will need to be implemented to change patients’ perceptions of the value of nicotinamide.
Findings of this recent study reveal the genetic features of patients with mucosal melanoma, mainly across six anatomic sites, offering a potential avenue for targeted therapies.
According to this recent study, genomic risk provision targeted to high-traditional melanoma risk individuals is likely a cost-effective strategy for reducing sunburns and will likely prevent future melanomas and keratinocyte carcinomas.
This study aims at clarifying the existence of the clinically invisible, early stages of actinic keratosis (AKs) on chronically UV-exposed skin without showing clinically evident features of AK.
Findings of this recent study suggest that long-term continuous irradiation with blue light induces neutrophil NETosis and an increase in type 1 macrophages, resulting in skin cancer.
According to this recent study, SIRT6 plays a role in skin carcinogenesis, and results of the study suggest SIRT6 pharmacological inhibition as a promising strategy in cutaneous Squamous Cell Carcinoma (cSCC).
Authors of this article review the role of immune checkpoints in melanoma; the history of melanoma immunotherapy; pivotal clinical trial data for ipilimumab, pembrolizumab, nivolumab and relatlimab; and the current clinical role of each immune checkpoint inhibitors (ICI). They also discuss challenges.
According to this recent molecular analysis of patients with resected melanoma brain metastases, BRAF V600E alteration is an important translational biomarker associated with worse clinical outcomes, differential microenvironmental composition, and benefit from immunotherapy. Patients with BRAF V600E variant melanoma brain metastases may thus benefit from alternative CNS-penetrant systemic regimens.